Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites

International Journal of Oncology

Volumn 30, Issue 4, 2007, Pages 889-898

  Ishiyama, Satoshi ^a   Matsueda, Satoko ^a   Jones, Lovell A ^a   Efferson, Clay ^a,b   Celestino, Joseph ^a   Schmandt, Rosemarie ^a   Ioannides, Constantin G ^a   Tsuda, Naotake ^a   Chang, David Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CTL; Notch; Numb; Ovarian cancer

Indexed keywords

HLA A2 ANTIGEN; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; NERVE PROTEIN; NOTCH1 RECEPTOR; NUMB PROTEIN, HUMAN; PEPTIDE; PROTEASOME; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; ASCITES; CD8+ T LYMPHOCYTE; CHEMISTRY; DIMERIZATION; FEMALE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; OVARY TUMOR; PROTEIN CONFORMATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ASCITES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DIMERIZATION; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; OVARIAN NEOPLASMS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; RECEPTOR, NOTCH1;

EID: 34247890110     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.4.889     Document Type: Article

References (39)

1. Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 284: 770-776, 1999. (Pubitemid 29291335)
2. Mumm JS, Schroeter EH, Saxena MT, et al: A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell 5: 197-206, 2000.
3. Ellisen LW, Bird J, West DC, et al: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-661, 1991. (Pubitemid 121001701)
4. Weng AP, Ferrando AA, Lee W, et al: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271, 2004. (Pubitemid 39336870)
5. Radtke F and Raj K: The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 3: 756-767, 2003.
6. Leong KG and Karsan A: Recent insights into the role of Notch signaling in tumorigenesis. Blood 107: 2223-2233, 2006. (Pubitemid 43345539)
7. Capobianco AJ, Zagouras P, Blaumueller CM, Artavanis-Tsakonas S and Bishop JM: Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol Cell Biol 17: 6265-6273, 1997. (Pubitemid 27451170)
8. Nickoloff BJ, Osborne BA and Miele L: Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22: 6598-6608, 2003.
9. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
10. Martinez Arias A, Zecchini V and Brennan K: CSL-independent Notch signalling: a checkpoint in cell fate decisions during development? Curr Opin Genet Dev 12: 524-533, 2002.
11. Guo M, Jan LY and Jan YN: Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Neuron 17: 27-41, 1996. (Pubitemid 26251589)
12. Rhyu MS, Jan LY and Jan YN: Asymmetric distribution of numb protein during division of the sensory organ precursor cell confers distinct fates to daughter cells. Cell 76: 477-491, 1994. (Pubitemid 24064169)
13. Santolini E, Puri C, Salcini AE, et al: Numb is an endocytic protein. J Cell Biol 151: 1345-1352, 2000.
14. Pece S, Serresi M, Santolini E, et al: Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 167: 215-221, 2004.
15. Stylianou S, Clarke RB and Brennan K: Aberrant activation of notch signaling in human breast cancer. Cancer Res 66: 1517-1525, 2006. (Pubitemid 43259933)
16. Gomez-Nunez M, Pinilla-Ibarz J, Dao T, et al: Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leuk Res 30: 1293-1298, 2006. (Pubitemid 44223735)
17. Bian H, Reidhaar-Olson JF and Hammer J: The use of bioinformatics for identifying class II-restricted T-cell epitopes. Methods 29: 299-309, 2003. (Pubitemid 36513446)
18. Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG and Schild H: PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 53: 87-94, 2001.
19. Kopp J and Schwede T: The Swiss-Model Repository: new features and functionalities. Nucleic Acids Res 34: D315-D318, 2006.
20. Zwahlen C, Li SC, Kay LE, Pawson T and Forman-Kay JD: Multiple modes of peptide recognition by the PTB domain of the cell fate determinant Numb. EMBO J 19: 1505-1515, 2000. (Pubitemid 30182158)
21. Ehebauer MT, Chirgadze DY, Hayward P, Martinez Arias A and Blundell TL: High-resolution crystal structure of the human Notch 1 ankyrin domain. Biochem J 392: 13-20, 2005. (Pubitemid 41689396)
22. Hambleton S, Valeyev NV, Muranyi A, et al: Structural and functional properties of the human notch-1 ligand binding region. Structure 12: 2173-2183, 2004. (Pubitemid 39593196)
23. Weijzen S, Rizzo P, Braid M, et al: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Rastransformed cells. Nat Med 8: 979-986, 2002.
24. Fisk B, Blevins TL, Wharton JT and Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109-2117, 1995.
25. Frischmann U and Muller W: Nine fluorescence parameter analysis on a four-color fluorescence activated flow cytometer. Cytometry A69: 124-126, 2006.
26. + cells to methylene groups appended to tumor antigen determines their differentiation or death. Cancer Res 65: 2930-2937, 2005.
27. Fahmy TM, Bieler JG, Edidin M and Schneck JP: Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity 14: 135-143, 2001. (Pubitemid 32206516)
28. Fahmy TM, Bieler JG and Schneck JP: Probing T cell membrane organization using dimeric MHC-Ig complexes. J Immunol Methods 268: 93-106, 2002.
29. Frahm N, Korber BT, Adams CM, et al: Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 78: 2187-2200, 2004.
30. Ellis JM, Henson V, Slack R, Ng J, Hartzman RJ and Katovich Hurley C: Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231. Hum Immunol 61: 334-340, 2000.
31. Li JL and Harris AL: Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell 8: 1-3, 2005.
32. Rehman AO and Wang CY: Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol 16: 293-300, 2006. (Pubitemid 43884979)
33. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW and Harris AL: Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65: 8690-8697, 2005. (Pubitemid 41377356)
34. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R and Ish-Horowicz D: Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69: 135-144, 2001. (Pubitemid 33755062)
35. Hainaud P, Contreres JO, Villemain A, et al: The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-Ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 66: 8501-8510, 2006. (Pubitemid 44449163)
36. Hopfer O, Zwahlen D, Fey MF and Aebi S: The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 93: 709-718, 2005. (Pubitemid 41486463)
37. Park JT, Li M, Nakayama K, et al: Notch3 gene amplification in ovarian cancer. Cancer Res 66: 6312-6318, 2006.
38. Sette A and Sidney J: Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50: 201-212, 1999. (Pubitemid 30099525)
39. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.